Rami Saade
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rami Saade has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
Elias Keyrouz
Lebanese American University Gilbert and Rose- Marie Chagoury, School of Medicine, Byblos, Lebanon; Department of Otolaryngology Head and Neck Surgery, Lebanese American University Medical Center, Beirut, Lebanon
3 shared publicationsAnita El Hajj
Speech Swallow Therapy, Lebanese American University Hospital Medical Center, Beirut, Lebanon
2 shared publicationsAnna Karena Issa
Lebanese American University Gilbert and Rose, Marie Chagoury, School of Medicine, Byblos, Lebanon
2 shared publicationsCaroline Jabbour
Lebanese American University Gilbert and Rose-Marie Chagoury, School of Medicine
2 shared publicationsHady Ghanem
Lebanese American University Gilbert and Rose-Marie Chagoury, School of Medicine
2 shared publicationsJana Hassan
Lebanese American University Gilbert and Rose-Marie Chagoury, School of Medicine
2 shared publications
Latest Publications
- Open Access
- 26 February 2026
- Published by Springer Nature in Cureus
- Vol. 18 (2)
Progressive Transformation of Germinal Centers: A Systematic Review
Progressive transformation of germinal centers (PTGC) is a benign histopathological process, typically manifesting as persistent, painless lymphadenopathy. It is of clinical significance because of its ability to mimic or coexist with other lymphoproliferative disorders. This systematic review summarizes the currently available literature to outline the clinical, pathological, and diagnostic features of PTGC and to identify areas that require further investigations to guide future clinical practice.
- 26 February 2026
- Published by Springer Nature in Cureus
- Vol. 18 (2)
Open AccessProgressive Transformation of Germinal Centers: A Systematic Review
Progressive transformation of germinal centers (PTGC) is a benign histopathological process, typically manifesting as persistent, painless lymphadenopathy. It is of clinical significance because of its ability to mimic or coexist with other lymphoproliferative disorders. This systematic review summarizes the currently available literature to outline the clinical, pathological, and diagnostic features of PTGC and to identify areas that require further investigations to guide future clinical practice.
- Open Access
- 25 February 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1780074
Prognostic factors in young patients with oral cavity cancer: a systematic review and meta-analysis of 24 studies
Background: Young-onset oral cancer is increasingly recognized as a distinct clinical entity, yet prognostic determinants in this population remain poorly defined. This systematic review and meta-analysis aimed to identify and synthesize prognostic factors associated with overall survival among young patients with oral and tongue cancers. Methods: A comprehensive search of PubMed, Scopus, and Web of Science was conducted on September 23, 2024. Eligible studies included observational cohorts reporting regression-derived prognostic estimates in young patients with oral cancer. Adjusted hazard ratios (aHRs) were pooled using random-effects models with restricted maximum likelihood, whereas unadjusted estimates were narratively summarized. Risk of bias was assessed using the NIH Quality Assessment Tool. Subgroup analyses were not feasible due to limited stratified reporting, and publication bias was not evaluated because all pooled analyses contained fewer than ten studies. Results: Twenty-four studies encompassing 6,965 young patients were included. Several demographic factors showed no significant association with survival, including age and sex, while Black race was associated with worse outcomes (aHR = 2.79, 95% CI 1.40–5.56). Tumor characteristics linked to poorer prognosis included larger tumor size (aHR = 1.01 per cm, 95% CI 1.00–1.03) and greater depth of invasion (aHR = 1.03, 95% CI 1.01–1.05). High-grade tumors (grade 3–4) (aHR = 2.15, 95% CI 1.52–2.77) and poorly differentiated histology (aHR = 7.75, 95% CI 2.61–23.01) demonstrated strong adverse prognostic associations. Nodal disease significantly increased risk, including higher N stage (aHR = 1.24, 95% CI 1.11–1.37) and N+ status (aHR = 2.05, 95% CI 1.24–2.85). Single-study findings—such as TERTp mutation (aHR = 3.00), PRKCA mutation (aHR = 3.57), Stage IVB, disease recurrence, and several treatment-related variables—suggest possible associations but remain inconclusive. Conclusions: Among young patients with oral and tongue cancer, nodal involvement, high-grade or poorly differentiated tumors, increased depth of invasion, and larger tumor size were the most consistently associated with poorer survival. Evidence for molecular and treatment-related factors is limited and requires further validation. These findings highlight the need for standardized reporting and prospective studies tailored to young-onset disease.
- 25 February 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1780074
Open AccessPrognostic factors in young patients with oral cavity cancer: a systematic review and meta-analysis of 24 studies
Background: Young-onset oral cancer is increasingly recognized as a distinct clinical entity, yet prognostic determinants in this population remain poorly defined. This systematic review and meta-analysis aimed to identify and synthesize prognostic factors associated with overall survival among young patients with oral and tongue cancers. Methods: A comprehensive search of PubMed, Scopus, and Web of Science was conducted on September 23, 2024. Eligible studies included observational cohorts reporting regression-derived prognostic estimates in young patients with oral cancer. Adjusted hazard ratios (aHRs) were pooled using random-effects models with restricted maximum likelihood, whereas unadjusted estimates were narratively summarized. Risk of bias was assessed using the NIH Quality Assessment Tool. Subgroup analyses were not feasible due to limited stratified reporting, and publication bias was not evaluated because all pooled analyses contained fewer than ten studies. Results: Twenty-four studies encompassing 6,965 young patients were included. Several demographic factors showed no significant association with survival, including age and sex, while Black race was associated with worse outcomes (aHR = 2.79, 95% CI 1.40–5.56). Tumor characteristics linked to poorer prognosis included larger tumor size (aHR = 1.01 per cm, 95% CI 1.00–1.03) and greater depth of invasion (aHR = 1.03, 95% CI 1.01–1.05). High-grade tumors (grade 3–4) (aHR = 2.15, 95% CI 1.52–2.77) and poorly differentiated histology (aHR = 7.75, 95% CI 2.61–23.01) demonstrated strong adverse prognostic associations. Nodal disease significantly increased risk, including higher N stage (aHR = 1.24, 95% CI 1.11–1.37) and N+ status (aHR = 2.05, 95% CI 1.24–2.85). Single-study findings—such as TERTp mutation (aHR = 3.00), PRKCA mutation (aHR = 3.57), Stage IVB, disease recurrence, and several treatment-related variables—suggest possible associations but remain inconclusive. Conclusions: Among young patients with oral and tongue cancer, nodal involvement, high-grade or poorly differentiated tumors, increased depth of invasion, and larger tumor size were the most consistently associated with poorer survival. Evidence for molecular and treatment-related factors is limited and requires further validation. These findings highlight the need for standardized reporting and prospective studies tailored to young-onset disease.
- Open Access
Outcomes for Sinonasal Undifferentiated Carcinoma (SNUC): An International Multi-Center Retrospective Cohort Study
Background: Sinonasal undifferentiated carcinoma (SNUC) is an extremely rare, high-grade, and aggressive tumor of the sinonasal tract. Due to the rarity of this malignancy, current treatment guidelines are based on small and often/mainly single-center retrospective datasets. In the absence of a universally accepted standard of care for SNUC, treatment approaches vary across countries and institutions, reflecting real-world clinical practice. The primary aim of this study was to describe real-world treatment and outcomes for patients with confirmed SNUC. Methods: This was an international, multi-center, retrospective, observational cohort study that pooled patients into the largest SNUC dataset to date. Fifteen centers were enrolled to contribute data, including seven from Europe, four from the United States, three from the United Kingdom, and one from Canada. In the absence of a universally accepted standard of care for SNUC, treatment approaches varied across countries and institutions, reflecting real-world clinical practice. Patients included were those with histologically confirmed SNUC who were treated between 1997 and 2021. Results: This study yielded 485 patients treated for SNUC. The median age at diagnosis was 55.6 years (IQR: 44.5–67.6), and 63.7% were male. Most cases presented at advanced stages, with 70.8% as T4a or T4b. Overall survival (OS) outcomes were available for 412 patients, with a median follow-up of 26.0 months. The 5- and 10-year OS were 47.2% (95% CI: 40.8–53.3%) and 39.6% (95% CI: 32.5–46.6%), respectively. Advanced age, dichotomized T-stage (T4a/b vs. T1–3), M-stage, and orbital involvement were significant poor prognostic factors on univariable analysis (p’s < 0.01). On multivariable analysis, orbital involvement (HR: 2.73, 95% CI: 1.42–5.27, p = 0.003) and distance metastasis stage (HR: 3.00, 95% CI: 1.25–7.21, p = 0.014) were both independently associated with worse OS. Conclusions: This observational study presents the largest multi-center cohort analysis of SNUC to date, providing new insights into prognostic factors for a rare cancer treated at global centers of excellence. Orbital involvement and the presence of metastases are candidate independent risk factors associated with poorer OS.
Open AccessOutcomes for Sinonasal Undifferentiated Carcinoma (SNUC): An International Multi-Center Retrospective Cohort Study
Background: Sinonasal undifferentiated carcinoma (SNUC) is an extremely rare, high-grade, and aggressive tumor of the sinonasal tract. Due to the rarity of this malignancy, current treatment guidelines are based on small and often/mainly single-center retrospective datasets. In the absence of a universally accepted standard of care for SNUC, treatment approaches vary across countries and institutions, reflecting real-world clinical practice. The primary aim of this study was to describe real-world treatment and outcomes for patients with confirmed SNUC. Methods: This was an international, multi-center, retrospective, observational cohort study that pooled patients into the largest SNUC dataset to date. Fifteen centers were enrolled to contribute data, including seven from Europe, four from the United States, three from the United Kingdom, and one from Canada. In the absence of a universally accepted standard of care for SNUC, treatment approaches varied across countries and institutions, reflecting real-world clinical practice. Patients included were those with histologically confirmed SNUC who were treated between 1997 and 2021. Results: This study yielded 485 patients treated for SNUC. The median age at diagnosis was 55.6 years (IQR: 44.5–67.6), and 63.7% were male. Most cases presented at advanced stages, with 70.8% as T4a or T4b. Overall survival (OS) outcomes were available for 412 patients, with a median follow-up of 26.0 months. The 5- and 10-year OS were 47.2% (95% CI: 40.8–53.3%) and 39.6% (95% CI: 32.5–46.6%), respectively. Advanced age, dichotomized T-stage (T4a/b vs. T1–3), M-stage, and orbital involvement were significant poor prognostic factors on univariable analysis (p’s < 0.01). On multivariable analysis, orbital involvement (HR: 2.73, 95% CI: 1.42–5.27, p = 0.003) and distance metastasis stage (HR: 3.00, 95% CI: 1.25–7.21, p = 0.014) were both independently associated with worse OS. Conclusions: This observational study presents the largest multi-center cohort analysis of SNUC to date, providing new insights into prognostic factors for a rare cancer treated at global centers of excellence. Orbital involvement and the presence of metastases are candidate independent risk factors associated with poorer OS.
- 18 September 2025
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 283 (2) , 671-682
Survival and larynx function after upfront vs. salvage total laryngectomy: a meta-analysis
Purpose Laryngeal cancer is a major malignancy in head and neck oncology, with total laryngectomy (TL) as a key intervention for advanced and recurrent disease. This systematic review and meta-analysis compare primary total laryngectomy (PTL) and salvage total laryngectomy (STL) in survival, functional outcomes, and complications. Methods A comprehensive search of PubMed, Scopus, Web of Science, and Google Scholar was conducted up to January 18, 2025. Studies comparing PTL and STL were included based on predefined eligibility criteria. Data extraction and quality assessment were performed independently by two reviewers. Random-effects models were used to calculate pooled odds ratios (ORs) and mean differences (MDs), with heterogeneity assessed via I² statistics. Sensitivity analyses ensured result robustness. Results Thirteen studies (2,704 patients: 913 STL, 1,791 PTL) met inclusion criteria. PTL showed significantly higher overall survival at 1 year (OR = 2.21; 95% CI: 1.38–3.55), 2 years (OR = 1.95; 95% CI: 1.40–2.71), and 3 years (OR = 1.64; 95% CI: 1.10–2.47). STL had higher risks of pharyngocutaneous fistula (OR = 2.78; 95% CI: 1.96–3.95) and reconstructive surgery (OR = 0.11; 95% CI: 0.02–0.75). PTL significantly reduced swallowing difficulty (OR = 0.12; 95% CI: 0.05–0.28) and hypopharyngeal stricture (OR = 0.14; 95% CI: 0.04–0.49). Speech functional outcomes showed no significant differences. Conclusion PTL improves survival and swallowing function with fewer complications, making it a preferred upfront treatment. STL remains essential for managing failures. Early identification of high-risk patients may improve clinical decision-making, optimizing survival and functional outcomes.
- 18 September 2025
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 283 (2) , 671-682
Survival and larynx function after upfront vs. salvage total laryngectomy: a meta-analysis
Purpose Laryngeal cancer is a major malignancy in head and neck oncology, with total laryngectomy (TL) as a key intervention for advanced and recurrent disease. This systematic review and meta-analysis compare primary total laryngectomy (PTL) and salvage total laryngectomy (STL) in survival, functional outcomes, and complications. Methods A comprehensive search of PubMed, Scopus, Web of Science, and Google Scholar was conducted up to January 18, 2025. Studies comparing PTL and STL were included based on predefined eligibility criteria. Data extraction and quality assessment were performed independently by two reviewers. Random-effects models were used to calculate pooled odds ratios (ORs) and mean differences (MDs), with heterogeneity assessed via I² statistics. Sensitivity analyses ensured result robustness. Results Thirteen studies (2,704 patients: 913 STL, 1,791 PTL) met inclusion criteria. PTL showed significantly higher overall survival at 1 year (OR = 2.21; 95% CI: 1.38–3.55), 2 years (OR = 1.95; 95% CI: 1.40–2.71), and 3 years (OR = 1.64; 95% CI: 1.10–2.47). STL had higher risks of pharyngocutaneous fistula (OR = 2.78; 95% CI: 1.96–3.95) and reconstructive surgery (OR = 0.11; 95% CI: 0.02–0.75). PTL significantly reduced swallowing difficulty (OR = 0.12; 95% CI: 0.05–0.28) and hypopharyngeal stricture (OR = 0.14; 95% CI: 0.04–0.49). Speech functional outcomes showed no significant differences. Conclusion PTL improves survival and swallowing function with fewer complications, making it a preferred upfront treatment. STL remains essential for managing failures. Early identification of high-risk patients may improve clinical decision-making, optimizing survival and functional outcomes.
- Open Access
- 1 January 2025
- Published by Wiley in Case Reports in Otolaryngology
- Vol. 2025 (1) , 6909432
Primary Posterior Neck Hydatid Cyst: A Case Report and Review of the Literature
Introduction: Hydatid cyst disease is an endemic parasitic infection caused by Echinococcus granulosus . Hydatid cysts occur mainly in the liver and lungs and are rare in the head and neck region, even in endemic areas. Due to their nonspecific clinical manifestations, diagnostic challenges are encountered in such atypical presentations. Case Presentation: We report the case of a 6‐year‐old girl who presented with a progressively enlarging, painless left postauricular mass. Radiological assessment revealed a well‐circumscribed, unilocular cystic lesion at level V of the neck. Surgical resection was performed, and histopathology confirmed a hydatid cyst. Postoperatively, the patient was treated with albendazole. No recurrence was observed at follow‐up. Clinical Discussion: Hydatid cysts in the cervical region are exceptionally rare, with only a few cases documented in the literature. The disease can remain asymptomatic for years, often presenting as a slow‐growing mass. Imaging with ultrasound and CT is critical in preoperative diagnosis. The gold standard of treatment remains complete surgical excision, reinforced by anthelmintic therapy to prevent recurrence. Conclusion: Although rare, hydatid cyst disease should remain among the differential diagnoses of cystic neck masses, especially in endemic areas. Early diagnosis and intervention are essential in evading complications of the disease such as anaphylaxis or recurrence. Ultimately, prevention remains the most effective strategy, emphasizing the need for community awareness, hygienic practices, and coordinated control efforts to break the parasite’s life cycle.
- 1 January 2025
- Published by Wiley in Case Reports in Otolaryngology
- Vol. 2025 (1) , 6909432
Open AccessPrimary Posterior Neck Hydatid Cyst: A Case Report and Review of the Literature
Introduction: Hydatid cyst disease is an endemic parasitic infection caused by Echinococcus granulosus . Hydatid cysts occur mainly in the liver and lungs and are rare in the head and neck region, even in endemic areas. Due to their nonspecific clinical manifestations, diagnostic challenges are encountered in such atypical presentations. Case Presentation: We report the case of a 6‐year‐old girl who presented with a progressively enlarging, painless left postauricular mass. Radiological assessment revealed a well‐circumscribed, unilocular cystic lesion at level V of the neck. Surgical resection was performed, and histopathology confirmed a hydatid cyst. Postoperatively, the patient was treated with albendazole. No recurrence was observed at follow‐up. Clinical Discussion: Hydatid cysts in the cervical region are exceptionally rare, with only a few cases documented in the literature. The disease can remain asymptomatic for years, often presenting as a slow‐growing mass. Imaging with ultrasound and CT is critical in preoperative diagnosis. The gold standard of treatment remains complete surgical excision, reinforced by anthelmintic therapy to prevent recurrence. Conclusion: Although rare, hydatid cyst disease should remain among the differential diagnoses of cystic neck masses, especially in endemic areas. Early diagnosis and intervention are essential in evading complications of the disease such as anaphylaxis or recurrence. Ultimately, prevention remains the most effective strategy, emphasizing the need for community awareness, hygienic practices, and coordinated control efforts to break the parasite’s life cycle.